CD8A and non-small cell lung carcinoma: Conversely, increased infiltration of cytotoxic T cells (CD8+) enhances the response to immune checkpoint inhibitors (ICIs), as observed in NSCLC patients with >10% CD8+ T cells in TME, who show 2.3-fold higher ORR to pembrolizumab than those with lower infiltration.